Announcements - OBI Pharma 台灣浩鼎

2020.Jul.29

TFDA clearance of passive immunotherapeutic monoclonal antibody OBI-888 for phase I/II human clinical studies

2020.Jul.22

Change in Phase III clinical study design for OBI-822 targeting TNBC and will continue the study with new clinical study design

2020.Jul.13

Resignation of representative of corporate director

2020.Jun.29

OBI filled application of Phase 1 human clinical study for active immunotherapeutic cancer vaccine, OBI-866, to TFDA

2020.Jun.23

Supplementary statements on news article

2020.Jun.22

Announcement of resolution items from 2020 Annual General Meeting

2020.Jun.22

Announcement of 2020 annual general meeting passes removal of the noncompete clause for directors

2020.Jun.10

OBI filled application of Phase 1 human clinical study for Novel Botulinum Toxin preparation, OBI-858, to TFDA

2020.May.29

OBI has filed application of Phase I/II human clinical studies for passive immunotherapeutic monoclonal antibody OBI-888 to TFDA

2020.May.26

OBI has signed a non-binding MOU to form a strategic partnership to develop novel bispecific antibody cancer treatments

News

Latest News

Events

Latest events